Personal Genome Diagnostics Inc. Sustainability Profile
Personal Genome Diagnostics Inc. (PGDx), headquartered in the United States, is a pioneering leader in the field of precision medicine and genomic testing. Founded in 2013, PGDx has rapidly established itself as a key player in the oncology diagnostics industry, focusing on the development of innovative genomic solutions for cancer patients. The company offers a range of unique products and services, including comprehensive genomic profiling and liquid biopsy tests, which enable clinicians to make informed treatment decisions based on individual tumour characteristics. PGDx's commitment to advancing cancer care is underscored by its notable achievements, including collaborations with leading research institutions and a growing portfolio of intellectual property. With a strong market position, PGDx continues to drive advancements in personalised medicine, helping to transform cancer treatment and improve patient outcomes across major operational regions in the US and beyond.
DitchCarbon Score
How does Personal Genome Diagnostics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Personal Genome Diagnostics Inc.'s score of 69 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Personal Genome Diagnostics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Labcorp Holdings Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges directly attributed to Personal Genome Diagnostics Inc., it is important to note that any potential climate initiatives or targets would likely be aligned with those of Labcorp Holdings Inc. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from Labcorp Holdings Inc. at a corporate family level. As of now, Personal Genome Diagnostics Inc. has not established specific reduction targets or initiatives, reflecting a broader context within the industry where many organisations are still developing their climate strategies. The absence of emissions data and reduction commitments suggests an opportunity for the company to enhance its sustainability efforts and align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 69,115,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 178,899,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Personal Genome Diagnostics Inc.'s Industry?
How Carbon Intensive is Personal Genome Diagnostics Inc.'s Location?
Personal Genome Diagnostics Inc.'s Scope 3 Categories Breakdown
Personal Genome Diagnostics Inc.'s Scope 3 emissions, which decreased by 4% last year and increased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 76% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
Personal Genome Diagnostics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Personal Genome Diagnostics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
